BioCentury | Dec 14, 2018
Clinical News

Syros' SY-1425 plus Vidaza leads to 63% ORR in biomarker-positive AML cohort

...in relapsed or refractory, biomarker-positive AML and high-risk MDS patients. Syros has exclusive rights from TMRC Co. Ltd....
...as Amnolake to treat relapsed/refractory acute promyelocytic leukemia (APL). Syros Pharmaceuticals Inc. (NASDAQ:SYRS), Cambridge, Mass. TMRC Co. Ltd....
...data Milestone: NA Brian Moy Amnolake, tamibarotene (SY-1425, am-80, INNO-507, TM-411, TOS-80T, Z-208) American Society of Hematology ASH Syros Pharmaceuticals Inc. TMRC Co. Ltd. Interferon...
BioCentury | Dec 15, 2017
Clinical News

Syros discontinues single agent tamibarotene

...the proportion of patients requiring supportive measures, pharmacokinetics and safety. Syros has exclusive rights from TMRC Co. Ltd....
...promyelocytic leukemia (APL) (see BioCentury, Oct. 19, 2015 ). Syros Pharmaceuticals Inc. (NASDAQ:SYRS), Cambridge, Mass. TMRC Co. Ltd....
...data Milestone: Additional Phase II data (2018) Allison Johnson azacitidine daratumumab Darzalex tamibarotene Vidaza American Society of Hematology Celgene Corp. Johnson & Johnson Syros Pharmaceuticals Inc. TMRC Co. Ltd. Interferon...
BioCentury | Dec 11, 2017
Clinical News

Syros falls on Phase II AML, MDS data

...Darzalex in relapsed or refractory AML and high-risk MDS patients. Syros has exclusive rights from TMRC Co. Ltd....
...to treat relapsed/refractory acute promyelocytic leukemia (APL). Allison Johnson azacitidine daratumumab Darzalex tamibarotene Vidaza American Society of Hematology Celgene Corp. Johnson & Johnson Syros Pharmaceuticals Inc. TMRC Co. Ltd. Interferon...
BioCentury | Apr 21, 2017
Financial News

Syros, SteadyMed complete private placements

...to treat acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). Syros has exclusive rights from TMRC Co. Ltd....
BioCentury | Apr 18, 2017
Distillery Therapeutics

Neurology

...with vehicle. Next steps could include identifying and testing additional compounds that promote MSR-1 expression. TMRC Co. Ltd....
...Co. Ltd. , and Syros Pharmaceuticals Inc. market Amnolake to treat acute promyelocytic leukemia (APL). TMRC...
BioCentury | Oct 3, 2016
Clinical News

Tamibarotene: Phase II started

...40 patients with a biomarker associated with the RARA pathway. Syros has exclusive rights from TMRC...
...Europe to treat cancer (see BioCentury, Oct. 19, 2015). Syros Pharmaceuticals Inc. (NASDAQ:SYRS), Cambridge, Mass. TMRC Co. Ltd....
BioCentury | Oct 19, 2015
Company News

TMRC, Syros deal

...RARA gene. Syros declined to disclose financial terms, and TMRC did not respond to inquiries. TMRC Co. Ltd....
BioCentury | May 13, 2013
Clinical News

Tamibarotene: Phase IIb discontinued

...rights to tamibarotene through its acquisition of Innovive Pharmaceuticals Inc. , which had rights from TMRC...
...SPA from FDA by year end or early 2014. CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. TMRC Co. Ltd....
BioCentury | Mar 4, 2013
Clinical News

Tamibarotene: Completed Phase IIb enrollment

...had rights from TMRC (see BioCentury, June 16, 2008). CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. TMRC Co. Ltd....
BioCentury | Aug 2, 2010
Clinical News

Tamibarotene: Phase II data

...had rights from TMRC (see BioCentury, June 16, 2008). CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. TMRC Co. Ltd....
Items per page:
1 - 10 of 26
BioCentury | Dec 14, 2018
Clinical News

Syros' SY-1425 plus Vidaza leads to 63% ORR in biomarker-positive AML cohort

...in relapsed or refractory, biomarker-positive AML and high-risk MDS patients. Syros has exclusive rights from TMRC Co. Ltd....
...as Amnolake to treat relapsed/refractory acute promyelocytic leukemia (APL). Syros Pharmaceuticals Inc. (NASDAQ:SYRS), Cambridge, Mass. TMRC Co. Ltd....
...data Milestone: NA Brian Moy Amnolake, tamibarotene (SY-1425, am-80, INNO-507, TM-411, TOS-80T, Z-208) American Society of Hematology ASH Syros Pharmaceuticals Inc. TMRC Co. Ltd. Interferon...
BioCentury | Dec 15, 2017
Clinical News

Syros discontinues single agent tamibarotene

...the proportion of patients requiring supportive measures, pharmacokinetics and safety. Syros has exclusive rights from TMRC Co. Ltd....
...promyelocytic leukemia (APL) (see BioCentury, Oct. 19, 2015 ). Syros Pharmaceuticals Inc. (NASDAQ:SYRS), Cambridge, Mass. TMRC Co. Ltd....
...data Milestone: Additional Phase II data (2018) Allison Johnson azacitidine daratumumab Darzalex tamibarotene Vidaza American Society of Hematology Celgene Corp. Johnson & Johnson Syros Pharmaceuticals Inc. TMRC Co. Ltd. Interferon...
BioCentury | Dec 11, 2017
Clinical News

Syros falls on Phase II AML, MDS data

...Darzalex in relapsed or refractory AML and high-risk MDS patients. Syros has exclusive rights from TMRC Co. Ltd....
...to treat relapsed/refractory acute promyelocytic leukemia (APL). Allison Johnson azacitidine daratumumab Darzalex tamibarotene Vidaza American Society of Hematology Celgene Corp. Johnson & Johnson Syros Pharmaceuticals Inc. TMRC Co. Ltd. Interferon...
BioCentury | Apr 21, 2017
Financial News

Syros, SteadyMed complete private placements

...to treat acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). Syros has exclusive rights from TMRC Co. Ltd....
BioCentury | Apr 18, 2017
Distillery Therapeutics

Neurology

...with vehicle. Next steps could include identifying and testing additional compounds that promote MSR-1 expression. TMRC Co. Ltd....
...Co. Ltd. , and Syros Pharmaceuticals Inc. market Amnolake to treat acute promyelocytic leukemia (APL). TMRC...
BioCentury | Oct 3, 2016
Clinical News

Tamibarotene: Phase II started

...40 patients with a biomarker associated with the RARA pathway. Syros has exclusive rights from TMRC...
...Europe to treat cancer (see BioCentury, Oct. 19, 2015). Syros Pharmaceuticals Inc. (NASDAQ:SYRS), Cambridge, Mass. TMRC Co. Ltd....
BioCentury | Oct 19, 2015
Company News

TMRC, Syros deal

...RARA gene. Syros declined to disclose financial terms, and TMRC did not respond to inquiries. TMRC Co. Ltd....
BioCentury | May 13, 2013
Clinical News

Tamibarotene: Phase IIb discontinued

...rights to tamibarotene through its acquisition of Innovive Pharmaceuticals Inc. , which had rights from TMRC...
...SPA from FDA by year end or early 2014. CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. TMRC Co. Ltd....
BioCentury | Mar 4, 2013
Clinical News

Tamibarotene: Completed Phase IIb enrollment

...had rights from TMRC (see BioCentury, June 16, 2008). CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. TMRC Co. Ltd....
BioCentury | Aug 2, 2010
Clinical News

Tamibarotene: Phase II data

...had rights from TMRC (see BioCentury, June 16, 2008). CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. TMRC Co. Ltd....
Items per page:
1 - 10 of 26